**Executive Summary**
Union Minister Dr. Jitendra Singh addressed the Confederation of Indian Industry (CII) Pharma & Life Sciences Summit 2025 on December 12, 2025, emphasizing the importance of judiciously using Artificial Intelligence (AI) in healthcare. The Minister highlighted the government's collaborative efforts with the private sector in biotechnology and gene therapy, urging industry leaders to leverage the newly announced ₹1 lakh crore R&D Fund to drive deep-tech projects. The speech underlines India's transition towards becoming a global exporter of preventive healthcare.
**Key Points / Main Content**
* **AI in Healthcare:**
* Judicious use of AI is crucial for the healthcare and pharma sectors.
* AI is an essential tool for diagnostics, drug discovery, and healthcare delivery.
* Integrating AI in a hybrid model balancing technology with human empathy is vital.
* AI-based diagnostic models are reducing culture testing time and improving patient outcomes through telemedicine.
* **Government-Industry Partnership:**
* The government is actively partnering with the private sector in areas such as gene therapy, biotechnology, and vaccine development.
* Department of Biotechnology (DBT) initiatives collaborate with private firms for indigenous solutions in areas like synthetic antibiotics, DNA and HPV vaccines, and bio-manufacturing.
* **R&D Funding:**
* The government has announced a ₹1 lakh crore R&D Fund to support deep-tech projects across health, agriculture, and other sectors.
* The government is financing private companies for innovation, marking a paradigm shift in India's R&D ecosystem.
* **India's Healthcare Transformation:**
* India is transitioning from an importer of curative healthcare to an exporter of preventive healthcare.
* The country is growing in global footprint in vaccines, biosimilars, and affordable medical devices.
* **Collaboration and Future of Healthcare:**
* Industry stakeholders are urged to act as partners in national progress and identify new areas for collaboration.
* Science, medicine, and technology are now part of a single ecosystem, and preparing for a larger, integrated role is essential in shaping the future of global healthcare.
**Impact Analysis**
**Industry Stakeholders (Pharma and Biotech Companies)**
* **Impact:**
* Opportunities to collaborate with the government on biotechnology and gene therapy projects.
* Access to government funding for R&D and innovation.
* Potential to contribute to India's transformation into a global healthcare exporter.
* **Action Required:**
* Explore partnership opportunities with the government.
* Leverage the ₹1 lakh crore R&D Fund for deep-tech projects.
* Act as partners in national progress and identify new areas for collaboration.
**Healthcare Sector**
* **Impact:**
* Potential for improved diagnostics, drug discovery, and healthcare delivery through AI integration.
* Opportunities for innovation and development of affordable, high-quality healthcare technologies.
* Enhanced patient confidence and outcomes through telemedicine services.
* **Action Required:**
* Focus on implementing AI solutions in healthcare.
* Collaborate on developing cost-effective health technologies.
* Prioritize human-centric approaches in AI implementation.
**General Public/Patients**
* **Impact:**
* Improved access to healthcare services through telemedicine, especially in remote areas.
* Potential for more effective diagnostics and treatments through AI-driven advancements.
* Increased patient confidence and better health outcomes.
* **Action Required:**
* Embrace new technology when prescribed by health professionals.
* Utilize the new resources available for optimal health.
Key Entities Referenced
Artificial Intelligence (AI): Emphasized as a tool for healthcare, diagnostics, drug discovery, and healthcare delivery.
Dr. Jitendra Singh: Union Minister of State for Science & Technology, Personnel, Public Grievances, Pensions, Atomic Energy and Space; the speaker at the event.
Department of Biotechnology (DBT): A department actively involved in collaborative initiatives with private firms for biotechnology and gene therapy development.
Confederation of Indian Industry (CII) Pharma & Life Sciences Summit 2025: The event where the minister spoke about AI's role in healthcare and India's biotech future.
R&D Fund: Government fund aimed to support research and development projects across various sectors, including health and agriculture.
Ministry of Science & Technology
Judicious use of Artificial Intelligence can be a
boon for healthcare: Dr Jitendra Singh
Government and industry partnership key to India’s biotech
future, Minister highlights growing public-private
collaboration in gene therapy and biotechnology
“India’s pharma sector transforming from importer to global
exporter of preventive healthcare”
प्रव तथ: 12 DEC 2025 4:55PM by PIB Delhi
NEW DELHI, December 12: Union Minister of State (Independent Charge) for Science & Technology;
Minister of State in the Prime Minister’s Office, Personnel, Public Grievances, Pensions, Atomic Energy
and Space, Dr. Jitendra Singh today emphasized that judicious use of Artificial Intelligence (AI) can be a
boon for healthcare pharma sectors, while underscoring the government’s strong collaboration with the
private sector in emerging biotechnology and gene therapy projects.
Addressing the Confederation of Indian Industry (CII) Pharma & Life Sciences Summit 2025, Dr. Jitendra
Singh said that the biggest transformation under Prime Minister Narendra Modi’s leadership has been that
the government reaches out to the industry with equal enthusiasm, reflecting a true whole-of-government,
whole-of-industry approach.
The Minister highlighted that AI is no longer a choice but an essential tool in diagnostics, drug discovery,
and healthcare delivery. He, however, said that its use has to be human-centric. “The real challenge is how
effectively we integrate AI in a hybrid model that balances technology with human empathy,” he
remarked.
Citing examples from healthcare innovation, he said AI-based diagnostic models are now reducing time
for culture testing from days to minutes, and telemedicine projects driven by AI are extending medical
services to remote villages in local dialects, significantly improving patient confidence and outcomes.
Highlighting India’s growing scientific and industrial capabilities, Dr. Jitendra Singh said that the
government is actively partnering with the private sector in frontier areas such as gene therapy,
biotechnology, and vaccine development. He mentioned that several Department of Biotechnology (DBT)
initiatives now operate in collaboration with leading private firms to develop indigenous solutions in areas
like synthetic antibiotics, DNA and HPV vaccines, and bio-manufacturing.
Referring to the government’s broader research push, the Minister invited industry leaders to leverage the
recently announced ₹1 lakh crore R&D Fund, which supports deep-tech projects across health,
agriculture, and other sectors. “For the first time, the government is financing private companies for
innovation — marking a paradigm shift in India’s R&D ecosystem,” he noted.Dr. Jitendra Singh also lauded India’s transition from being an importer of curative healthcare to an
exporter of preventive healthcare, citing the country’s growing global footprint in vaccines, biosimilars,
and affordable medical devices. “We are now producing high-quality, cost-effective health technologies
that are finding markets across the world,” he added.
Concluding his address, the Minister urged industry stakeholders to act as partners in national progress,
not only leading their own sectors but also suggesting new areas for collaboration. “Science, medicine,
and technology are now part of a single ecosystem, and together we must prepare for a larger, integrated
role in shaping the future of global healthcare,” he said.*****
NKR/AK
(रलीज़ आईडी: 2203065) आगंतुक पटल : 470
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही